Structure of LRRK2 in Parkinson's disease and model for microtubule interaction.

Benzamides / pharmacology Biocatalysis / drug effects Cryoelectron Microscopy Dimerization Dyneins / antagonists & inhibitors Humans Kinesins / antagonists & inhibitors Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 / antagonists & inhibitors Microtubules / chemistry Models, Molecular Movement / drug effects Parkinson Disease / metabolism Protein Binding Protein Domains / drug effects Pyrazoles / pharmacology WD40 Repeats

Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
12 2020
Historique:
received: 10 11 2019
accepted: 12 08 2020
pubmed: 20 8 2020
medline: 2 3 2021
entrez: 20 8 2020
Statut: ppublish

Résumé

Leucine-rich repeat kinase 2 (LRRK2) is the most commonly mutated gene in familial Parkinson's disease

Identifiants

DOI: 10.1038/s41586-020-2673-2 PMID: 32814344 PMC: PMC7726071
pubmed: 32814344
doi: 10.1038/s41586-020-2673-2
pii: 10.1038/s41586-020-2673-2
pmc: PMC7726071
mid: NIHMS1620036
doi:

Substances chimiques

Benzamides 0
Pyrazoles 0
LRRK2 protein, human EC 2.7.11.1
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 EC 2.7.11.1
Dyneins EC 3.6.4.2
Kinesins EC 3.6.4.4
olverembatinib KV1M7Q3CBP

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

344-349

Subventions

Organisme : Howard Hughes Medical Institute
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM107214
Pays : United States
Organisme : NIH HHS
ID : S10 OD018111
Pays : United States
Organisme : NIGMS NIH HHS
ID : U24 GM116792
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NCRR NIH HHS
ID : S10 RR023057
Pays : United States
Organisme : NIGMS NIH HHS
ID : DP2 GM123494
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM121772
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008326
Pays : United States

Commentaires et corrections

Type : CommentIn

Références

J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Elife. 2017 Nov 10;6:
pubmed: 29125462
Nat Chem Biol. 2011 Apr;7(4):203-5
pubmed: 21378983
Science. 2008 Feb 22;319(5866):1086-9
pubmed: 18202255
Biochem J. 2015 Jan 1;465(1):139-47
pubmed: 25317655
Nat Methods. 2012 Sep;9(9):853-4
pubmed: 22842542
J Biol Chem. 2006 Aug 11;281(32):23167-79
pubmed: 16707497
Nature. 2016 Nov 09;539(7628):207-216
pubmed: 27830778
Proc Natl Acad Sci U S A. 2019 Jul 23;116(30):14979-14988
pubmed: 31292254
Methods Mol Biol. 2014;1136:171-246
pubmed: 24633799
J Cell Biol. 2019 May 6;218(5):1619-1633
pubmed: 30814157
Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1579-1584
pubmed: 30635421
Structure. 2012 Feb 8;20(2):205-14
pubmed: 22325770
Proc Natl Acad Sci U S A. 2016 Jul 26;113(30):E4357-66
pubmed: 27357661
J Struct Biol. 2009 Apr;166(1):95-102
pubmed: 19263523
Hum Mol Genet. 2012 Feb 15;21(4):890-9
pubmed: 22080837
Nat Methods. 2017 Mar;14(3):290-296
pubmed: 28165473
Elife. 2016 Sep 26;5:
pubmed: 27669148
Cell. 1997 Jul 25;90(2):207-16
pubmed: 9244295
Nat Commun. 2014 Oct 15;5:5245
pubmed: 25316291
Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W244-8
pubmed: 15980461
J Pharmacol Exp Ther. 2015 Dec;355(3):397-409
pubmed: 26407721
Dev Cell. 2020 Apr 6;53(1):60-72.e4
pubmed: 32109385
PLoS One. 2010 Oct 27;5(10):e13672
pubmed: 21060682
Elife. 2017 Jul 18;6:
pubmed: 28718761
J Cell Sci. 2010 Jan 15;123(Pt 2):181-91
pubmed: 20026645
Nat Cell Biol. 2020 May;22(5):518-525
pubmed: 32341549
Biochem J. 2019 Jan 7;476(1):51-66
pubmed: 30538153
J Mol Biol. 2003 Oct 31;333(4):721-45
pubmed: 14568533
Elife. 2016 Jan 29;5:
pubmed: 26824392
Cell. 2020 Sep 17;182(6):1508-1518.e16
pubmed: 32783917
J Cell Biol. 2019 Sep 2;218(9):2982-3001
pubmed: 31320392
Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1499-504
pubmed: 18230735
Biochemistry. 2013 Mar 12;52(10):1725-36
pubmed: 23379419
Nat Cell Biol. 2002 Dec;4(12):986-92
pubmed: 12447383
Cell. 2007 Jun 15;129(6):1177-87
pubmed: 17574028
Chem Biol. 2015 Sep 17;22(9):1174-84
pubmed: 26320862
Ultramicroscopy. 2013 Dec;135:24-35
pubmed: 23872039
J Struct Biol. 2004 Jan-Feb;145(1-2):91-9
pubmed: 15065677
Hum Mol Genet. 2006 Jan 15;15(2):223-32
pubmed: 16321986
J Med Chem. 2017 Apr 13;60(7):2983-2992
pubmed: 28245354
J Cell Sci. 2019 Feb 19;132(5):
pubmed: 30700496
Biochem Biophys Res Commun. 2009 Nov 20;389(3):449-54
pubmed: 19733152
Nat Cell Biol. 2008 Nov;10(11):1269-79
pubmed: 18849981
Biochem J. 2018 Jan 2;475(1):1-22
pubmed: 29127256
J Med Chem. 2011 Apr 14;54(7):2341-50
pubmed: 21391610
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
pubmed: 15572765
Biochemistry. 2007 Feb 6;46(5):1380-8
pubmed: 17260967
Science. 2012 Jan 13;335(6065):221-5
pubmed: 22157083
Elife. 2018 Nov 09;7:
pubmed: 30412051
Hum Mol Genet. 2007 Jan 15;16(2):223-32
pubmed: 17200152
Structure. 2010 Aug 11;18(8):1022-31
pubmed: 20696402
Nat Struct Mol Biol. 2012 Jan 08;19(2):193-200
pubmed: 22231401
Hum Mol Genet. 2017 Jul 15;26(14):2747-2767
pubmed: 28453723
Commun Biol. 2019 Jun 19;2:218
pubmed: 31240256
J Med Chem. 2013 Feb 14;56(3):879-94
pubmed: 23301703
Nat Methods. 2017 Apr;14(4):331-332
pubmed: 28250466
J Struct Biol. 2005 Jul;151(1):41-60
pubmed: 15890530
Sci Transl Med. 2018 Jan 10;10(423):
pubmed: 29321258
Cell. 2006 Jul 28;126(2):335-48
pubmed: 16873064
Sci Transl Med. 2018 Jul 25;10(451):
pubmed: 30045977
J Med Chem. 2015 May 14;58(9):3751-6
pubmed: 25897865
Cell. 1997 Sep 5;90(5):959-66
pubmed: 9298907
EMBO J. 2008 Aug 20;27(16):2239-49
pubmed: 18650931
Adv Neurobiol. 2017;14:3-30
pubmed: 28353276
Sci Rep. 2017 Aug 17;7(1):8667
pubmed: 28819229

Auteurs

C K Deniston (CK)

Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA.
Genomics Institute of the Novartis Research Foundation, La Jolla, CA, USA.

J Salogiannis (J)

Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA.
Howard Hughes Medical Institute, Chevy Chase, MD, USA.

S Mathea (S)

Institute of Pharmaceutical Chemistry, Goethe-Universität, Frankfurt, Germany.

D M Snead (DM)

Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA.
ORCID: 0000-0001-7839-452X

I Lahiri (I)

Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA.
Department of Biological Sciences, Indian Institute of Science Education and Research Mohali, Mohali, India.

M Matyszewski (M)

Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA.

O Donosa (O)

Howard Hughes Medical Institute, Chevy Chase, MD, USA.
ORCID: 0000-0002-1871-447X

R Watanabe (R)

Division of Biological Sciences, Molecular Biology Section, University of California San Diego, La Jolla, CA, USA.
La Jolla Institute for Immunology, La Jolla, CA, USA.

J Böhning (J)

Division of Biological Sciences, Molecular Biology Section, University of California San Diego, La Jolla, CA, USA.
Sir William Dunn School of Pathology, Oxford University, Oxford, UK.
ORCID: 0000-0002-6242-1041

A K Shiau (AK)

Small Molecule Discovery Program, Ludwig Institute for Cancer Research, La Jolla, CA, USA.
Division of Biological Sciences, Cell and Developmental Biology Section, University of California San Diego, La Jolla, CA, USA.

S Knapp (S)

Institute of Pharmaceutical Chemistry, Goethe-Universität, Frankfurt, Germany.
ORCID: 0000-0001-5995-6494

E Villa (E)

Division of Biological Sciences, Molecular Biology Section, University of California San Diego, La Jolla, CA, USA.
ORCID: 0000-0003-4677-9809

S L Reck-Peterson (SL)

Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA. sreckpeterson@ucsd.edu.
Howard Hughes Medical Institute, Chevy Chase, MD, USA. sreckpeterson@ucsd.edu.
Division of Biological Sciences, Cell and Developmental Biology Section, University of California San Diego, La Jolla, CA, USA. sreckpeterson@ucsd.edu.
ORCID: 0000-0002-1553-465X

A E Leschziner (AE)

Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA. aleschziner@ucsd.edu.
Division of Biological Sciences, Molecular Biology Section, University of California San Diego, La Jolla, CA, USA. aleschziner@ucsd.edu.
ORCID: 0000-0002-7732-7023

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Hydrocarbures cycliques › Hydrocarbures aromatiques › Dérivés du benzène › Benzoates › Benzamides › Structure of LRRK2 in Parkinson's disease and...
questionsmedicales.fr › Métabolisme › Biocatalyse › Structure of LRRK2 in Parkinson's disease and...
questionsmedicales.fr › Techniques d'investigation › Microscopie électronique › Cryomicroscopie électronique › Structure of LRRK2 in Parkinson's disease and...
questionsmedicales.fr › Métabolisme › Dimérisation › Structure of LRRK2 in Parkinson's disease and...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines du cytosquelette › Protéines microtubulaires › Dynéines › Structure of LRRK2 in Parkinson's disease and...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Structure of LRRK2 in Parkinson's disease and...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines de tissu nerveux › Protéines associées aux microtubules › Kinésine › Structure of LRRK2 in Parkinson's disease and...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines associées à la maladie de Parkinson › Leucine-rich repeat serine-threonine protein kinase-2 › Structure of LRRK2 in Parkinson's disease and...
questionsmedicales.fr › Cellules › Structures cellulaires › Espace intracellulaire › Cytoplasme › Structures cytoplasmiques › Cytosquelette › Microtubules › Structure of LRRK2 in Parkinson's disease and...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles moléculaires › Structure of LRRK2 in Parkinson's disease and...
questionsmedicales.fr › Phénomènes physiologiques de l'appareil locomoteur et du système nerveux › Phénomènes physiologiques du système locomoteur › Mouvement › Structure of LRRK2 in Parkinson's disease and...
questionsmedicales.fr › Maladies du système nerveux › Maladies neurodégénératives › Maladie de Parkinson › Structure of LRRK2 in Parkinson's disease and...
questionsmedicales.fr › Métabolisme › Liaison aux protéines › Structure of LRRK2 in Parkinson's disease and...
questionsmedicales.fr › Phénomènes chimiques › Phénomènes biochimiques › Conformation moléculaire › Conformation des protéines › Structure tertiaire des protéines › Domaines protéiques › Structure of LRRK2 in Parkinson's disease and...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Azoles › Pyrazoles › Structure of LRRK2 in Parkinson's disease and...
questionsmedicales.fr › Phénomènes chimiques › Phénomènes biochimiques › Conformation moléculaire › Conformation des protéines › Éléments structuraux des protéines › Séquences répétées d'acides aminés › Répétitions WD40 › Structure of LRRK2 in Parkinson's disease and...